Teva Pharma is trading at $33.60 (+6.09%) in pre-market following second-quarter 2026 results that highlighted a successful pivot toward its branded portfolio.
- Revenue reached $4.1 billion with 43% growth in innovative brands, as AUSTEDO, AJOVY, and UZEDY collectively surpassed $1 billion in quarterly revenue for the first time.
- Despite an EPS miss attributed to acquisition costs, investor sentiment remains bullish due to the significant revenue beat and accelerating momentum in the company's high-margin branded segment.